Amarin Corp Plc (AMRN)

[Biobillionair]

Akanz...the use of Crestor was a pure negotiation tactic in my opinion. First it puts Pfizer on notice that Amarin has intensions of getting the highest dollar for their assests. Then in the PR JZ makes it crystal clear of the IP protection Amarin's has secured with all patents.

My advise to Amarin is apply for orphan status in the Anchor application. Dr. Wood wrote a great article on pediactric Trigylceremia and it's likely orphan status. Vascepa's taste is very mild and could be compounded easily with flavoring.

I suspect he's actually the one running the FDA via Dr. Janet Woodcock and C-Path.


http://www.mc.vanderbilt.edu/reporter/index.html?ID=2118

Hedge Funds have full access to the FDA through C-Path.